Intas Pharmaceuticals Acquires UDENYCA from Coherus BioSciences
Intas Pharmaceuticals, along with its global subsidiaries operating under the Accord brand, has acquired UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences, strengthening its global biosimilar portfolio and strengthening its position in the pegfilgrastim market.
Binish Chudgar | 07/08/2025 | By Mrinmoy Dey
Intas Pharmaceuticals has launched HETRONIFLY (Serplulimab), the world’s first PD-1 inhibitor approved for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the Indian market.
Binish Chudgar | 06/08/2025 | By Mrinmoy Dey | 131
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy